当雄激素剥夺疗法中加入前列腺局部放疗时，小体积同步转移性激素敏感性前列腺癌 (mHSPCa) 患者的生存获益得到证实。本研究旨在确定接受和未接受 mHSPCa 外照射放疗的患者中前列腺癌相关事件和治疗的发生率。 HORRAD 试验是一项多中心随机对照试验，最初招募了 2004 年至 2004 年间诊断的 432 名 mHSPCa 患者。 2014 年。在第二次更新的分析中，对 328 名患者的局部和非局部前列腺癌相关事件和治疗进行了回顾性研究。结果测量包括局部（膀胱出口或输尿管梗阻、导管插入、手术干预、输尿管支架和肾造口管）和非局部（输血、住院和疼痛性骨转移治疗）事件的发生率和治疗。使用粗略和调整后的逻辑回归比较组间差异，同时使用 Kaplan-Meier 曲线和 Cox 回归分析评估局部事件发生时间。观察到局部事件发生率存在显着差异：放疗组 30 例事件，而放疗组 30 例事件。非放射治疗组为 50 例 (p = 0.04)。放疗组进行局部干预的时间明显更长（风险比 0.61，95% 置信区间 0.37-0.99，p = 0.04）。该研究的局限性包括其回顾性。前列腺局部放疗可显着延长 mHSPCa 患者的局部无事件生存期，并减少与局部前列腺癌相关的干预措施。版权所有 © 2024 欧洲泌尿外科协会。由 Elsevier B.V. 出版。保留所有权利。

A survival benefit was demonstrated for patients with low-volume synchronous metastatic hormone-sensitive prostate cancer (mHSPCa) when local radiotherapy to the prostate was added to androgen deprivation therapy. This study aims to determine the incidence of prostate cancer-related events and treatments in those who received and those who did not receive external beam radiotherapy for mHSPCa.The HORRAD trial is a multicentre randomised controlled trial recruiting originally 432 patients with mHSPCa diagnosed between 2004 and 2014. In a second updated analysis, 328 patients were studied retrospectively for local and nonlocal prostate cancer-related events and treatments. Outcome measurements included the incidence and treatment of local (bladder outlet or ureter obstruction, catheterisation, surgical intervention, ureteric stents, and nephrostomy tubes) and nonlocal (blood transfusions, hospitalisations, and treatment for painful bone metastases) events. Differences between groups were compared using crude and adjusted logistic regression, while time to occurrence of local events was assessed with Kaplan-Meier curves and Cox regression analysis.A significant difference in the incidence of local events was observed: 30 events in the radiotherapy group versus 50 in the nonradiotherapy group (p = 0.04). Time to occurrence of local interventions was significantly longer in the radiotherapy group (hazard ratio 0.61, 95% confidence interval 0.37-0.99, p = 0.04). The study's limitations include its retrospective nature.Local radiotherapy to the prostate prolongs local event-free survival significantly and reduces local prostate cancer-related interventions in patients with mHSPCa.Copyright © 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved.